 The FDA has designated Breakthrough Therapy status to Kura Oncology Incs NASDAQ: KURA tipifarnib, an orally bioavailable inhibitor of farnesyl transferase for head and neck cancer. The status covers recurrent or metastatic HRAS mutant head and neck squamous cell carcinoma HNSCC with a variant allele frequency of more than 20 after disease progression on platinum-based chemotherapy. 